Literature DB >> 22212303

Addition of rituximab to high-dose methotrexate-based chemotherapy improves survival of adults with Burkitt lymphoma/leukemia.

Dino Dujmovic1, Igor Aurer, Ivo Radman, Ranka Serventi-Seiwerth, Snjezana Dotlic, Ranka Stern-Padovan, Klara Dubravcic, Fedor Santek, Boris Labar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22212303     DOI： 10.1159/000334705

Source DB:  PubMed          Journal:  Acta Haematol        ISSN： 0001-5792            Impact factor:   2.195


× No keyword cloud information.
  2 in total

Review 1.  Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers.

Authors:  Tanya M Wildes; Laura Farrington; Cecilia Yeung; Alexandra M Harrington; Kelley V Foyil; Jingxia Liu; Friederike Kreisel; Nancy L Bartlett; Timothy S Fenske
Journal:  Ther Adv Hematol       Date:  2014-02

2.  Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma.

Authors:  James L Rubenstein; Jing Li; Lingjing Chen; Ranjana Advani; Jan Drappatz; Elizabeth Gerstner; Tracy Batchelor; Hendrikus Krouwer; James Hwang; Glenna Auerback; Cigall Kadoch; Clifford Lowell; Pamela Munster; Soonmee Cha; Marc A Shuman; Lloyd E Damon
Journal:  Blood       Date:  2012-11-29       Impact factor: 22.113
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.